40.66
+1.52(+3.88%)
Currency In USD
| Previous Close | 39.14 |
| Open | 38.66 |
| Day High | 40.78 |
| Day Low | 38.24 |
| 52-Week High | 53.27 |
| 52-Week Low | 22.35 |
| Volume | 957,918 |
| Average Volume | 441,307 |
| Market Cap | 2.63B |
| PE | -17.38 |
| EPS | -2.34 |
| Moving Average 50 Days | 46 |
| Moving Average 200 Days | 41.33 |
| Change | 1.52 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,222.49 as of December 21, 2024 at a share price of $40.66. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $692.79 as of December 21, 2024 at a share price of $40.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced tha
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
GlobeNewswire Inc.
Nov 05, 2024 12:00 PM GMT
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced tha
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire Inc.
Oct 31, 2024 11:30 AM GMT
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to acce